What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2024-08-08 compared with 2024-05-08 · 220 added, 237 removed, 210 unchanged (69% of the section changed)

1 unchanged sentence

Immunocore Holdings plc

Condensed Consolidated

Balance Sheets

Condensed Consolidated Balance Sheets

(Unaudited) (In thousands, except share and per share data)

2024 December 31,

Current assets

Cash and cash equivalents $ 504,985 $ 442,626

Marketable securities

Accounts receivable, net 60,245 52,093

6 unchanged sentences

Other non-current assets 16,276 14,473

Total assets $ 1,023,365 $ 597,001

Liabilities and shareholders’ equity

10 unchanged sentences

Shareholders’ equity

Ordinary shares (voting and non-voting), £ 0.002

par value, most recent authority to allot up to a maximum nominal value of £ 97,454 and £ 109,335 shares as of March 31, 2024 and December 31, 2023, respectively, and 50,006,085 and 49,725,649 shares issued and outstanding as of

March 31, 2024 and December 31, 2023, respectively.

Deferred shares, £ 0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of March 31, 2024 and December 31, 2023.

Ordinary shares (voting and non-voting), £ 0.002 par value, most recent authority to allot up to a maximum nominal value of £ 97,454 and £ 109,355 shares as of June 30, 2024 and December 31, 2023, respectively, and 50,017,606 and 49,725,649 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively.

Deferred shares, £ 0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of June 30, 2024 and December 31, 2023.

Additional paid-in capital 1,174,147 1,149,643

5 unchanged sentences

Immunocore Holdings plc

Condensed Consolidated Statements of

Operations and Comprehensive Loss

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited) (In thousands, except share and per share data)

Three Months Ended March 31,

Three Months Ended June 30, Six Months Ended June 30,

2024 2023 2024 2023

Product revenue, net $ 75,347 $ 56,932 $ 145,689 $ 108,513

10 unchanged sentences

Foreign currency loss

Other expense, net

( 508 ) ( 5,880 ) ( 2,914 ) ( 11,893 )

Other income (expense), net

4,433 ( 190 ) 4,243 ( 515 )

Net loss before income taxes ( 10,130 ) ( 16,823 ) ( 34,209 ) ( 35,979 )

Income tax expense

( 1,486 ) ( 191 ) ( 1,843 ) ( 484 )

Net loss $ ( 11,616 ) $ ( 17,014 ) $ ( 36,052 ) $ ( 36,463 )

Other comprehensive income:

5 unchanged sentences

Immunocore Holdings plc

Condensed Consolidated

Statements of Shareholders’ Equity

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited) (In thousands, except share data)

Ordinary Shares

Deferred Shares

comprehensive

Shareholders’

As of December 31, 2023

Ordinary Shares Deferred Shares Additional Paid-in Capital Accumulated

deficit Accumulated other comprehensive (loss) income Total Shareholders' Equity

Shares Amount Shares Amount

As of March 31, 2024

50,006,085 $ 135 5,793,501 $ 1 $ 1,163,872 $ ( 769,110 ) $ ( 35,364 ) $ 359,534

Net loss — — — — — ( 11,616 ) — ( 11,616 )

Other comprehensive income — — — — — — 944 944

1 unchanged sentence

Share-based compensation expense — — — — 9,978 — — 9,978

As of June 30, 2024

50,017,606 $ 135 5,793,501 $ 1 $ 1,174,147 $ ( 780,726 ) $ ( 34,420 ) $ 359,137

Ordinary Shares Deferred Shares Additional Paid-in Capital Accumulated

deficit Accumulated other comprehensive (loss) income Total Shareholders' Equity

Shares Amount Shares Amount

As of March 31, 2023

Ordinary Shares

Deferred Shares

comprehensive

Shareholders’

48,379,409 $ 130 5,793,501 $ 1 $ 1,097,248 $ ( 708,836 ) $ ( 47,239 ) $ 341,304

Net loss — — — — — ( 17,014 ) — ( 17,014 )

Other comprehensive income — — — — — — 6,771 6,771

Exercise of share options 561,940 2 — — 11,556 — — 11,558

Share-based compensation expense — — — — 8,821 — — 8,821

As of June 30, 2023

48,941,349 $ 132 5,793,501 $ 1 $ 1,117,625 $ ( 725,850 ) $ ( 40,468 ) $ 351,440

The accompanying notes form an integral part of these condensed consolidated financial statements.

Immunocore Holdings plc

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited) (In thousands, except share data)

Ordinary Shares Deferred Shares Additional Paid-in Capital Accumulated

deficit Accumulated other comprehensive (loss) income Total Shareholders' Equity

Shares Amount Shares Amount

As of December 31, 2023 49,725,649 $ 134 5,793,501 $ 1 $ 1,149,643 $ ( 744,674 ) $ ( 36,261 ) $ 368,843

Net loss — — — — — ( 36,052 ) — ( 36,052 )

Other comprehensive income — — — — — — 1,841 1,841

1 unchanged sentence

Share-based compensation expense — — — — 18,995 — — 18,995

As of March 31, 2023

As of June 30, 2024 50,017,606 $ 135 5,793,501 $ 1 $ 1,174,147 $ ( 780,726 ) $ ( 34,420 ) $ 359,137

Ordinary Shares Deferred Shares Additional Paid-in Capital Accumulated

deficit Accumulated other comprehensive (loss) income Total Shareholders' Equity

Shares Amount Shares Amount

As of December 31, 2022 48,088,346 $ 129 5,793,501 $ 1 $ 1,082,833 $ ( 689,387 ) $ ( 54,673 ) $ 338,903

Net loss — — — — — ( 36,463 ) — ( 36,463 )

Other comprehensive income — — — — — — 14,205 14,205

Exercise of share options 853,003 3 — — 17,713 — — 17,716

Share-based compensation expense — — — — 17,079 — — 17,079

As of June 30, 2023 48,941,349 $ 132 5,793,501 $ 1 $ 1,117,625 $ ( 725,850 ) $ ( 40,468 ) $ 351,440

The accompanying notes form an integral part of these condensed consolidated financial statements.

2 unchanged sentences

(Unaudited) (In thousands)

Three Months Ended March 31,

Six Months Ended June 30,

Cash flows from operating activities

Net loss $ ( 36,052 ) $ ( 36,463 )

Adjustments for:

Share-based compensation expense 18,964 17,079

Depreciation 2,003 1,981

Unrealized foreign exchange losses

Unrealized gains on marketable securities

Non-cash lease expense 864 808

2 unchanged sentences

(Increase) decrease in prepayments and other current assets

Decrease in accounts payable

( 4,058 ) 15,704

Increase in accounts payable 2,164 2,962

Increase in accrued expenses 46,031 11,878

1 unchanged sentence

Decrease in operating lease liabilities ( 1,136 ) ( 906 )

Increase in other operating assets

Increase (decrease) in other operating liabilities

Net cash (used in) provided by operating activities

Decrease (increase) in other operating assets

Increase in other operating liabilities

Net cash provided by operating activities

18,885 10,584

Cash flows from investing activities

Purchase of marketable securities

( 350,000 ) —

Purchase of property and equipment

( 761 ) ( 4,396 )

Net cash used in investing activities ( 350,761 ) ( 4,396 )

Cash flows from financing activities

Proceeds from issue of convertible loan notes

Proceeds from issue of convertible senior notes

Payments for debt issuance costs ( 13,358 ) —

7 unchanged sentences

Cash received for interest, net

$ 12,117 $ 4,451

Cash paid for income taxes, net

Debt issuance costs in accrued expenses and other current liabilities

$ ( 59 ) $ ( 220 )

Purchases of property and equipment in accrued expenses and other current liabilities $ — $ 239

3 unchanged sentences

Description of business

Immunocore Holdings plc (collectively with its subsidiaries, the “Company”) is a public limited company incorporated in England and

Wales and has the following wholly owned subsidiaries:

Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited with operations based primarily in the United

Kingdom and United States.

Immunocore Holdings plc (collectively with its subsidiaries, the “Company”) is a public limited company incorporated in England and Wales and has the following wholly owned subsidiaries:

Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited with operations based primarily in the United Kingdom and United States.

The Company is pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases.

Leveraging its proprietary, flexible, off-the-shelf ImmTAX ( Immune mobilizing monoclonal TCRs Against X disease) platform, the Company’s pipeline includes nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases.

Leveraging its proprietary, flexible, off-the-shelf ImmTAX (Immune mobilizing monoclonal TCRs Against X disease) platform, the Company’s pipeline includes nine active clinical and preclinical programs in oncology, infectious diseases, and autoimmune diseases.

In January and April 2022, the Company received approval from the U.S.

Food and Drug Administration, or FDA, and European Commission, or EC,

respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma and has subsequently received approvals in further territories, and the Company continues to launch and seek approvals in additional

KIMMTRAK is now approved in 38 countries and the Company has commercially launched the product in the United States,

Germany and France, among other territories.

Food and Drug Administration ("FDA") and European Commission, ("EC"), respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma and has subsequently received approvals in further territories, and the Company continues to launch and seek approvals in additional territories.

KIMMTRAK is now approved in 38 countries and the Company has commercially launched the product in the United States, Germany and France, among other territories.

Summary of significant accounting policies

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally

accepted in the U.S., or U.S.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S.

GAAP"), for interim financial reporting and pursuant to the requirements for reporting on Form 10-Q and Article 10 of Regulation S-X.

Accordingly, they do not include all of the information required for the full

annual financial statements and should be read in conjunction with the annual consolidated financial statements of the Company for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the Securities

and Exchange Commission, or the SEC, on February 28, 2024, or the Annual Report.

The accompanying condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, results

of operations, and cash flows for the interim periods reported.

In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring

Accordingly, they do not include all of the information required for the full annual financial statements and should be read in conjunction with the annual consolidated financial statements of the Company for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), on February 28, 2024 ("Annual Report").

The accompanying condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods reported.

In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments.

Certain information and footnote disclosures have been condensed or omitted as permitted under U.S.

The results for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the

year ending December 31, 2024, any other interim periods, or any future year or period.

The results for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period.

Use of estimates

The preparation of the condensed consolidated financial statements in conformity with U.S.

GAAP requires management to make judgments, estimates and

GAAP requires management to make judgments, estimates and assumptions.

These judgments, estimates and assumptions affect the reported assets and liabilities as well as income and expenses in the financial period.

The estimates and associated assumptions are based on information available when the condensed consolidated financial statements are prepared,

historical experience and various other factors which are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent

from other sources.

Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond

the Company’s control.

The estimates and associated assumptions are based on information available when the condensed consolidated financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the Company’s control.

Actual results could differ from those estimates.

Estimates are primarily made in relation to revenue recognition, estimation of operating lease incremental borrowing rates, share-based compensation expense, clinical

accruals, and deferred tax asset valuation allowances.

Estimates are primarily made in relation to revenue recognition, estimation of operating lease incremental borrowing rates, share-based compensation expense, clinical accruals, and deferred tax asset valuation allowances.

Significant accounting policies

With the exception of the below polices, the significant accounting policies used in the preparation of these condensed consolidated financial

statements as of and for the three months ended March 31, 2024 are consistent with those described in Note 2.

“Summary of Significant Accounting Policies” in the Company’s

Annual Report.

With the exception of the below polices, the significant accounting policies used in the preparation of these condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 are consistent with those described in No te 2.

"Summary of Significant Accounting Policies" in the Company’s Annual Report.

Collaboration and supply agreements

In February 2024, the Company entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb, or BMS, to investigate the

Company’s ImmTAC bispecific TCR candidate targeting PRAME HLA-A02, brenetafusp (IMC-F106C), in combination with BMS’s nivolumab, in first-line advanced cutaneous melanoma, or the BMS Agreement.

Under the terms of the collaboration, the Company

will sponsor and fund the registrational Phase 3 clinical trial of brenetafusp in combination with nivolumab in first-line advanced cutaneous melanoma (PRISM-MEL-301), and BMS will provide nivolumab.

Both parties will own the study data produced

in the clinical trial, other than study data related solely to nivolumab, which will belong solely to BMS, or study data related solely to IMC-F106C, which will belong solely to the Company.

Given the terms of the BMS Agreement, the Company

concluded that it is not within the scope of ASC 808 or ASC 606.

Any relevant costs arising from the clinical trial will be expensed as incurred and recorded in research and development expenses.

The Company will initiate the clinical trial for

the combination therapy of nivolumab and IMC-F106C in the second quarter of 2024.

There has been no impact to the condensed consolidated financial statements as of March 31, 2024 relating to the Company’s collaboration with BMS.

In February 2024, the Company entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb ("BMS"), to investigate the Company’s ImmTAC bispecific TCR candidate targeting PRAME HLA-A02, brenetafusp (IMC-F106C), in combination with BMS’s nivolumab, in first-line advanced cutaneous melanoma (the "BMS Agreement").

Under the terms of the BMS Agreement, the Company is sponsoring and funding the registrational Phase 3 clinical trial of brenetafusp in combination with nivolumab in first-line advanced cutaneous melanoma (PRISM-MEL-301), and BMS is providing nivolumab.

Both parties will own the study data produced in the clinical trial, other than study data related solely to nivolumab, which will belong solely to BMS, or study data related solely to brenetafusp, which will belong solely to the Company.

Given the terms of the BMS Agreement, the Company concluded that it is not within the scope of ASC 808 or ASC 606.

Any relevant costs arising from the clinical trial are expensed as incurred and recorded in research and development expenses.

The Company has announced the randomization of the first patient in the PRISM-MEL 301 trial in June 2024.

There has been no impact to the condensed consolidated financial statements as of June 30, 2024 relating to the Company’s collaboration with BMS.

Convertible senior notes

The Company issued 2.5 % Convertible Senior Notes due

in 2030 in February 2024, or the Notes, and evaluated to determine whether they contain features that qualify as embedded derivatives in accordance with ASC 815.

Embedded derivatives must be separately measured from the host contract if all the

requirements for bifurcation are met.

The Company issued 2.5 % Convertible Senior Notes due in 2030 in February 2024 (the "Notes"), and evaluated to determine whether they contain features that qualify as embedded derivatives in accordance with ASC 815.

Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met.

The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives.

In accounting for the issuance of the

Notes, the Company treats the instrument wholly as a liability, in accordance with ASC 470, as the conversion features do not require bifurcation as a derivative in accordance with ASC 815 and the Notes were not issued at a substantial premium.

Costs directly associated with the borrowing have been capitalized and are netted against the corresponding debt liabilities in the Company’s Condensed Consolidated Balance Sheets at issuance and amortized over the contractual term of the

convertible debt instrument using the effective interest rate method .

In accounting for the issuance of the Notes, the Company treats the instrument wholly as a liability, in accordance with ASC 470, as the conversion features do not require bifurcation as a derivative in accordance with ASC 815 and the Notes were not issued at a substantial premium.

“Non-current interest-bearing loans and borrowings” for additional information.

2 unchanged sentences

Effective January 1, 2024, the Company’s ultimate parent adopted the U.S.

its functional currency.

dollar as its functional currency.

Prior to January 1, 2024, the functional currency of the Company’s ultimate parent was the British pound sterling.

The functional currency of the Company’s ultimate parent and each subsidiary is based on the currency of

the economic environment in which they operate.

The functional currency of the Company’s ultimate parent and each subsidiary is based on the currency of the economic environment in which they operate.

The change in functional currency of the Company’s ultimate parent is due to a change in the economic facts and circumstances of the entity due to the increased exposure to the U.S.

dollar primarily

as a result of the increased cash flows related to financing and investing activities that are now expected to occur going forward in this entity.

The effect of the change in functional currency for the Company’s ultimate parent was applied

prospectively in the condensed consolidated financial statements effective January 1, 2024.

Upon consolidation, assets and liabilities of each subsidiary with a functional currency that differs to the Company’s ultimate parent are

translated into U.S.

dollar primarily as a result of the increased cash flows related to financing and investing activities that are now expected to occur going forward in this entity.

The effect of the change in functional currency for the Company’s ultimate parent was applied prospectively in the Condensed Consolidated Financial Statements effective January 1, 2024.

Upon consolidation, assets and liabilities of each subsidiary with a functional currency that differs to the Company’s ultimate parent are translated into U.S.

dollars at period-end exchange rates, and revenues and expenses are translated into U.S.

dollars using average exchange rates for each reporting period.

Translation adjustments are reflected as other comprehensive (loss)

Translation adjustments are reflected as other comprehensive income (loss).

Marketable securities

Marketable securities consist of investment funds which are measured and reported at fair value determined using quoted market prices.

The investment funds are primarily invested in U.S.

investment-grade debt securities, including asset-backed and mortgage-backed securities.

Marketable securities are available to the Company for use in current operations and are classified as current assets.

Gains and losses from marketable securities are recognized in Other income (expense), net.

Fair value measurements

Where financial and non-financial assets and liabilities are measured at fair value, the Company uses appropriate valuation techniques for which

sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

As of March 31, 2024 and December 31, 2023, the Company held $ 726.0 million and $ 331.0 million, respectively, of money market funds required to be measured at fair

value on a recurring basis.

The fair value of these cash equivalents is based on quoted prices from active markets (Level 1 inputs).

Other financial instruments, although not recorded at fair value on a recurring basis, include cash, accounts

receivable, accounts payable and debt obligations.

The fair value of borrowings under the Notes and Pharmakon Loan Agreement (disclosed in

“Non-current interest-bearing loans and borrowings”) were based on Level 2 inputs, which include observable inputs estimated using discounted cash flows and market-based expectations for interest rates, credit risk, and the contractual

terms of debt instruments.

Where financial and non-financial assets and liabilities are measured at fair value, the Company uses appropriate valuation techniques for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

As of June 30, 2024 and December 31, 2023, the Company held $ 383.1 million and $ 331.0 million, respectively, of money market funds required to be measured at fair value on a recurring basis within cash and cash equivalents.

In addition, as of June 30, 2024, and December 31, 2023, the Company held $ 354.6 million and $ 0 of marketable securities, respectively, including unrealized gains of $ 4.6 million and $ 0 , respectively.

The fair value of these cash equivalents and marketable securities is based on quoted prices from active markets (Level 1 inputs).

Other financial instruments, although not recorded at fair value on a recurring basis, include cash, accounts receivable, accounts payable and debt obligations.

The fair value of borrowings under the Notes and Pharmakon Loan Agreement (disclosed in Note 5.

After initial recognition, borrowings are measured at amortized cost using the effective interest method.

2 unchanged sentences

33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors .

The final rule requires registrants to provide climate-related disclosures in their annual reports and registration

statements, beginning with annual reports for the year ending December 31, 2025, for calendar-year-end large accelerated filers.

The Company is currently assessing the impact of this guidance on its disclosures.

During the three months ended March 31, 2024, the Company recognized $ 70.3 million (2023:

$ 51.6 million) of net product revenue relating to the sale of KIMMTRAK primarily

in the United States and Europe after estimated deductions for rebates, chargebacks, other customer fees and returns, which are recognized in Accrued expenses and other current liabilities as set out in the Company’s accounting policies included

in the Annual Report.

The final rule requires registrants to provide climate-related disclosures in their annual reports and registration statements, beginning with annual reports for the year ending December 31, 2025, for calendar-year-end large accelerated filers.

In April 2024, the SEC issued an order staying the final rule pending the completion of legal challenges to the final rule.

The Company is currently assessing the impact of this final rule and the order to stay the rule on its disclosures.

During the three and six months ended June 30, 2024, the Company recognized $ 75.3 million and $ 145.7 million, respectively, (2023:

$ 56.9 million and $ 108.5 million, respectively) of net product revenue relating to the sale of KIMMTRAK primarily in the United States and Europe after estimated deductions for rebates, chargebacks and returns, which are recognized in Accrued expenses and other current liabilities as set out in the Company’s accounting policies included in the Annual Report.

Product revenue, net from the sale of KIMMTRAK is presented by country / region based on the location of the end customer below (in thousands):

Three Months Ended March 31,

Three Months Ended June 30, Six Months Ended June 30,

2024 2023 2024 2023

United States $ 55,606 $ 41,056 $ 105,632 $ 77,281

Europe 15,404 15,232 34,356 30,356

International 4,337 644 5,701 876

Total product revenue, net $ 75,347 $ 56,932 $ 145,689 $ 108,513

Product revenue, net for the three months ended March 31, 2024 and the three months ended March 31, 2023 includes $ 2.2 million and $ 0.9 million,

respectively, of partnered revenue under the Company’s agreement with Medison Pharma Ltd, or Medison, and such revenue is split between its European and international markets.

Collaboration revenue for the three months ended March 31, 2024 and March 31, 2023 was $ 0.2 million and $ 3.1 million, respectively, and arose under the Company’s

collaboration agreement with Genentech who is based in the United States.

Product revenue, net for the three and six months ended June 30, 2024 includes $ 5.0 million and $ 7.2 million respectively (2023:

$ 2.0 million and $ 1.1 million, respectively), of partnered revenue under the Company's agreement with Medison Pharma Ltd ("Medison"), and such revenue is split between its European and international markets.

Accounts receivable from contracts with customers

Accounts receivable as of March 31, 2024 and December 31, 2023 was $ 57.8 million and $ 52.1 million, respectively.

An allowance for lifetime expected credit losses on

accounts receivable is measured using historical credit loss experience, conditions at the end of each reporting period, and reasonable and supportable forecasts that affect collectability.

Expected credit losses as of March 31, 2024 and December

31, 2023 were immaterial.

Accounts receivable as of June 30, 2024 and December 31, 2023 was $ 60.2 million and $ 52.1 million, respectively.

An allowance for lifetime expected credit losses on accounts receivable is measured using historical credit loss experience, conditions at the end of each reporting period, and reasonable and supportable forecasts that affect collectability.

Expected credit losses as of June 30, 2024 and December 31, 2023 were immaterial.

Accruals for rebates, chargebacks and returns

Current and non-current accruals for rebates, chargebacks and returns as of March 31, 2024 were as follows (in thousands):

Current and non-current accruals for rebates, chargebacks and returns as of June 30, 2024 were as follows (in thousands):

Rebates Chargebacks Returns Total

As of December 31, 2023 $ 63,957 $ 2,031 $ 738 $ 66,726

2 unchanged sentences

Credits and payments made ( 11,717 ) ( 15,590 ) ( 672 ) ( 27,979 )

As of March 31 , 2024

Included in the above are non-current accruals for rebates, chargebacks and returns of $ 1.1 million and $ 0 as of March 31, 2024, and December 31, 2023, respectively, which are not expected

to be paid in the twelve months from the balance sheet date.

For accruals for rebates, chargebacks and returns reported as of December 31, 2023 where the uncertainty remains unresolved, additional

information in the three months ended March 31, 2024 resulted in a change in estimate of $ 5.4 million net increase to the Company’s

total accrued revenue deductions as of March 31, 2024.

As of June 30, 2024 $ 104,451 $ 1,957 $ 615 $ 107,023

Included in the above are non-current accruals for rebates, chargebacks and returns of $ 1.5 million and $ 0 as of June 30, 2024 and December 31, 2023, respectively, which are not expected to be paid in the twelve months from the balance sheet date.

For accruals for rebates, chargebacks and returns reported as of December 31, 2023 where the uncertainty remains unresolved, additional information in the three and six months ended June 30, 2024 resulted in a change in estimate of $ 5.8 million and $ 11.2 million, respectively, net increase to the Company’s total accrued revenue deductions as of June 30, 2024.

Deferred revenue

Non-current deferred revenue as of March 31, 2024 and December 31, 2023 relates to $ 5.0 million received from Medison in the year ended December 31, 2023.

The Company expects to recognize revenue for this combined performance obligation of supplying

KIMMTRAK and granting Medison the exclusive right to distribute KIMMTRAK in South America with the sale of products following regulatory approval in South America.

The Company estimates that product revenue recognition of this non-current

deferred revenue will commence later than March 31, 2025.

Non-current deferred revenue as of June 30, 2024 and December 31, 2023 relates to $ 5.0 million received from Medison in the year ended December 31, 2023.

The Company expects to recognize revenue for this combined performance obligation of supplying KIMMTRAK and granting Medison the exclusive right to distribute KIMMTRAK in South America with the sale of products following potential regulatory approvals in South America.

The Company estimates that product revenue recognition of this non-current deferred revenue will commence later than June 30, 2025.

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consists of the following (in thousands):

Rebates, chargebacks, other customer fees and returns

2024 December 31,

Rebates, chargebacks and returns

$ 105,547 $ 66,726

Clinical accruals 29,447 22,459

Contract manufacturing

Commercial services

Employee related expenses 8,626 11,598

Commercial services 5,930 6,900

Contract manufacturing 5,327 4,356

Other taxation and social security 992 1,807

Other accruals 7,893 5,989

$ 163,762 $ 119,835

“Revenue” for a detailed breakdown of rebates, chargebacks, other customer fees and returns.

Clinical accruals primarily represent unbilled work undertaken by contract research organizations, or CROs, as part of the advancement of the

Company’s clinical programs.

Clinical accruals primarily represent unbilled work undertaken by contract research organizations ("CROs") as part of the advancement of the Company's clinical programs.

Non-current interest-bearing loans and borrowings

Non-current interest-bearing loans and borrowings consists of the following (in thousands) as of March 31, 2024:

Non-current interest-bearing loans and borrowings consists of the following as of June 30, 2024 (in thousands):

Principal Amount

2 unchanged sentences

Convertible senior notes

$ 402,500 $ ( 12,527 ) $ 389,973 $ 333,712 Level 2

Pharmakon loan

Non-current interest-bearing loans and borrowings consists of the following (in thousands) as of December 31, 2023:

50,000 ( 1,852 ) 48,148 55,384 Level 2

Non-current interest-bearing loans and borrowings consists of the following as of December 31, 2023 (in thousands):

Principal Amount

Unamortized Debt Discount and Issuance Costs

Unamortized Debt Issuance Costs

Net Carrying Amount

2 unchanged sentences

Pharmakon loan

50,000 ( 1,989 ) 48,011 46,100 Level 2

Interest expense consists of the following (in thousands):

Three Months Ended March 31,

Three Months Ended June 30,

Six Months Ended June 30,

2024 2023 2024 2023

Convertible senior notes

Coupon interest

$ 2,480 $ — $ 4,107 $ —

Amortization of debt issuance costs

Pharmakon loan

Interest expense

On February 2, 2024, the Company completed a private offering, or the Offering, of $ 402.5 million aggregate principal amount of Notes, including the exercise in full of the initial purchasers’ option to purchase up to an additional $ 52.5 million principal amount of Notes.

The Notes were issued pursuant to an indenture, dated February 2, 2024, or the Indenture, between the Company

1,284 1,274 2,577 2,524

Total interest expense

$ 4,277 $ 1,274 $ 7,516 $ 2,524

On February 2, 2024, the Company completed a private offering ("the Offering") of $ 402.5 million aggregate principal amount of Notes, including the exercise in full of the initial purchasers’ option to purchase up to an additional $ 52.5 million principal amount of Notes.

The Notes were issued pursuant to an indenture, dated February 2, 2024 (the "Indenture") between the Company and U.S.

Bank Trust Company, National Association, as trustee.

The Company’s net proceeds from the Offering of the Notes were $ 389.1

million, after deducting issuance costs of $ 13.4 million.

The Company’s net proceeds from the Offering of the Notes were $ 389.1 million, after deducting issuance costs of $ 13.4 million.

The Notes are senior, unsecured obligations of the Company and will mature on February 1, 2030, unless earlier converted, redeemed or repurchased.

The Notes will accrue interest payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024, at a rate of 2.50 % per year.

As of March 31, 2024, lender fees and issuance costs incurred with the Notes were $ 13.4 million and are being amortized as interest expense on an effective interest rate method over the expected life of the Notes, through February 2030, at an effective interest rate of 3.06 %.

Holders may convert all or any portion of their Notes at their option at any time prior to the close of business on the business day immediately preceding the

maturity date.

The Notes have an initial conversion rate of 10.5601 American Depository Shares or ADSs per $ 1,000 principal amount of the Notes, which will be subject to anti-dilution adjustments in certain circumstances.

This represented an initial

conversion price of $ 94.70 per ADS.

As of March 31, 2024, the number of shares that would be issuable assuming conversion of all of the

Notes is 5,950,600 (assuming the maximum increase to the conversion rate in connection with a “make-whole fundamental change” (as

defined in the Indenture)).

Upon conversion, the Notes may be settled in shares of the Company’s ordinary shares, cash or a combination of cash and shares of the Company’s ordinary shares, at the Company’s

Upon the occurrence of a make-whole fundamental change (as defined in the Indenture), the Company may, in certain circumstances, be required to increase the conversion rate by a number of additional shares for a holder that elects to

convert its Notes in connection with such make-whole fundamental change.

L ender fees and issuance costs incurred with the Notes were $ 13.4 million and are being amortized as interest expense on an effective interest rate method over the expected life of the Notes, through February 2030, at an effective interest rate of 3.06 %.

Holders may convert all or any portion of their Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date.

The Notes have an initial conversion rate of 10.5601 American Depositary Shares ("ADSs") per $ 1,000 principal amount of the Notes, which will be subject to anti-dilution adjustments in certain circumstances.

This represented an initial conversion price of $ 94.70 per ADS.

The number of shares that would be issuable assuming conversion of all of the Notes is 5,950,600 (assuming the maximum increase to the conversion rate in connection with a “make-whole fundamental change” (as defined in the Indenture)).

Upon conversion, the Notes may be settled in shares of the Company’s ordinary shares, cash or a combination of cash and shares of the Company’s ordinary shares, at the Company’s election.

The Company may not redeem the Notes prior to February 5, 2027, except in the event of certain tax law changes as described below and in the Indenture.

may redeem for cash all or any portion of the Notes (subject to the partial redemption limitation described in the Indenture), at its option, on or after February 5, 2027 if the last reported sale price of the ADSs has been at least 130 % of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive

trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of optional redemption, at a redemption price equal to 100 % of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the optional redemption date.

If, as a result of certain changes in the law of any relevant tax jurisdiction the Company would be required to pay additional amounts (as defined in the Indenture)

on the Notes, the Company may redeem the Notes in whole, but not in part, at a tax redemption price of 100 % of the aggregate principal

amount thereof, plus accrued and unpaid interest to, but excluding, the tax redemption date and all additional amounts, if any, which otherwise would be payable to the date of tax redemption.

Upon the Company giving notice of a tax redemption, a

holder may elect not to have its Notes redeemed, in which case the holder would not be entitled to receive any additional amounts with respect to its Notes after the tax redemption date.

If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their

Notes at a repurchase price equal to 100 % of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

On November 8, 2022, the Company entered into the Pharmakon loan agreement, or the Pharmakon Loan Agreement, providing for term loans to the Company

in an aggregate principal amount of up to $ 100 million to be funded in two tranches.

The first tranche of $ 50 million bears interest at a fixed rate

of 9.75 %, which is payable quarterly in arrears, with payments commencing in 2023.

The Company is also required to pay a further fee

of $ 1.25 million at the latest by June 2024, regardless of whether it elects to draw down on the second $ 50 million tranche under the Pharmakon Loan Agreement.

The second tranche, consisting of one or two term loan(s) of up to $ 50 million is available until June 30, 2024, and may be advanced at the Company’s election.

The Company may redeem for cash all or any portion of the Notes (subject to the partial redemption limitation described in the Indenture), at its option, on or after February 5, 2027 if the last reported sale price of the ADSs has been at least 130 % of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of optional redemption, at a redemption price equal to 100 % of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the optional redemption date.

If, as a result of certain changes in the law of any relevant tax jurisdiction, the Company would be required to pay additional amounts (as defined in the Indenture) on the Notes, the Company may redeem the Notes in whole, but not in part, at a tax redemption price of 100 % of the aggregate principal amount thereof, plus accrued and unpaid interest to, but excluding, the tax redemption date and all additional amounts, if any, which otherwise would be payable to the date of tax redemption.

Upon the Company giving notice of a tax redemption, a holder may elect not to have its Notes redeemed, in which case the holder would not be entitled to receive any additional amounts with respect to its Notes after the tax redemption date.

If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Notes at a repurchase price equal to 100 % of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

On November 8, 2022, the Company entered into the Pharmakon loan agreement (the "Pharmakon Loan Agreement"), providing for term loans to the Company in an aggregate principal amount of up to $ 100 million to be funded in two tranches.

The first tranche of $ 50 million bears interest at a fixed rate of 9.75 %, which is payable quarterly in arrears, with payments commencing in 2023.

The Company was required to pay a further fee of $ 1.25 million at the latest by June 2024, regardless of whether it elected to draw down on the second $ 50 million tranche under the Pharmakon Loan Agreement.

The Company elected not to exercise the option to drawn down the second tranche and made the payment of $ 1.25 million in the three months ended June 30, 2024.

The Pharmakon Loan Agreement has a maturity of November 8, 2028.

The Company has pledged its total assets of $ 994.0

million, presented in the Condensed Consolidated Balance Sheet as of March 31, 2024, as collateral for the $ 50 million loan drawn down

under the Pharmakon Loan Agreement.

In the event the Company was unable to repay the loan, the pledged assets may instead be used to repay the outstanding amount of loan and interest.

The Company’s borrowings under the Pharmakon Loan Agreement, contain customary representations and warranties and customary affirmative and negative

covenants, including limitations on the Company’s ability to dispose of assets, enter into merger, consolidation or acquisition transactions, and incur additional debt.

The Company monitors these covenants and is in compliance as of the date of

this Quarterly Report.

As of March 31, 2024, future principal payments are due as follows (in thousands):

The Company has pledged its total assets of $ 1,023.4 million, presented in the Condensed Consolidated Balance Sheet as of June 30, 2024, as collateral for the $ 50 million loan drawn down under the Pharmakon Loan Agreement.

In the event the Company is unable to repay the loan, the pledged assets may instead be used to repay the outstanding amount of loan and interest.

The Company’s borrowings under the Pharmakon Loan Agreement, contain customary representations and warranties and customary affirmative and negative covenants, including limitations on the Company’s ability to dispose of assets, enter into merger, consolidation or acquisition transactions, and incur additional debt.

The Company monitors these covenants and is in compliance as of the date of this Quarterly Report.

As of June 30, 2024, future principal payments due are as follows (in thousands):

2029 and thereafter

3 unchanged sentences

Share-based compensation

Under the Company’s Equity Incentive Plan, or EIP, the Company may grant market value options, share appreciation rights or restricted shares,

restricted share units, performance share units and other share-based awards to the Company’s employees.

Under the Company’s Equity Incentive Plan ("EIP"), the Company may grant market value options, share appreciation rights or restricted shares, restricted share units, performance share units and other share-based awards to the Company’s employees.

The Company’s board members and consultants are eligible to receive awards under the Company’s non-employee sub-plan to the EIP.

be granted at such times as the Company may determine, but will generally be granted annually following the end of the financial year.

Awards may be granted at such times as the Company may determine, but will generally be granted annually following the end of the financial year.

Awards vest at such times and as specified in the award agreement, typically being over a four-year period although the Company retains the discretion to provide for other vesting schedules.

If the participant violates the non-competition,

non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, the right of the participant to receive these shares on vesting shall terminate immediately.

The Company maintains discretion over the

type and terms of equity awards granted.

If the participant violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, the right of the participant to receive these shares on vesting shall terminate immediately.

The Company maintains discretion over the type and terms of equity awards granted.

All awards lapse on the tenth anniversary from the date of grant, and they are not subject to performance conditions or entitled to dividends.

The Company has reserved 5,608,325 authorized shares for future issuance under the EIP.

The following table shows the total share-based compensation expense recorded in the Condensed Consolidated Statements of Operations and

Comprehensive Loss (in thousands):

Three Months Ended March 31,

The following table shows the total share-based compensation expense recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands):

Three Months Ended June 30, Six Months Ended June 30,

2024 2023 2024 2023

Research and development

$ 2,172 $ 1,841 $ 4,152 $ 3,537

Selling, general and administrative $ 7,828 $ 6,980 $ 14,812 $ 13,542

1 unchanged sentence

The number and weighted average exercise prices of share options are as follows:

Share Options (#)

Exercise Price ($)

Contractual Term

Intrinsic Value

(in thousands)

Outstanding as of December 31, 2023

Number of share options (#) Weighted Average exercise price ($) Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands)

Outstanding as of December 31, 2023 8,967,882 $ 27.06 7.1 years $ 369,976

Awards granted 995,731 68.26

1 unchanged sentence

Awards forfeited ( 31,452 ) 43.42

Outstanding as of March 31, 2024

Exercisable as of March 31, 2024

As of March 31, 2024, total unrecognized compensation expense related to share options granted but not vested was $ 56.7 million, which the Company expects to recognize over a remaining weighted-average period of 1.2 years.

Awards granted in the three months ended March 31, 2024 and 2023 have been valued using the Black-Scholes option pricing model.

The assumptions used

in the models for share options granted during the three months ended March 31, 2024 and 2023, are as follows:

Three Months Ended March 31,

Outstanding as of June 30, 2024 9,640,204 $ 31.51 7.0 years $ 22,962

Exercisable as of June 30, 2024 6,612,926 $ 24.31 6.4 years $ 58,876

As of June 30, 2024, total unrecognized compensation expense related to share options granted but not vested was $ 50.2 million, which the Company expects to recognize over a remaining weighted-average period of 1.1 years.

Awards granted in the three and six months ended June 30, 2024 and 2023 have been valued using the Black-Scholes option pricing model.

The assumptions used in the models for share options granted during the three and six months ended June 30, 2024 and 2023, are as follows:

Three Months Ended June 30, Six Months Ended June 30,

2024 2023 2024 2023

Share price at grant date $ 46.05 - $ 62.94

1 unchanged sentence

$ 46.05 - $ 70.05

$ 48.38 - $ 64.53

Exercise price $ 46.05 - $ 62.94

1 unchanged sentence

$ 46.05 - $ 70.05

$ 48.38 - $ 64.53

Expected volatility 55.24 % - 57.04 %

1 unchanged sentence

55.24 % - 66.17 %

Expected life (years)

71.02 % - 72.05 %

Expected life (years) 5.5 years 5 years

5 years - 5.5 years

3 unchanged sentences

3.52 % - 4.06 %

Fair value $ 25.23 - $ 34.99

$ 29.51 - $ 35.87

Share options are not entitled to receive dividends.

$ 25.23 - $ 40.47

$ 29.51 - $ 39.92

Basic and diluted net loss per share

Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):

Three Months Ended March 31,

Three Months Ended June 30, Six Months Ended June 30,

2024 2023 2024 2023

$ ( 11,616 ) $ ( 17,014 ) $ ( 36,052 ) $ ( 36,463 )

Basic and diluted weighted-average number of shares outstanding 50,014,086 48,694,047 49,944,767 48,440,318

Basic and diluted net loss per share $ ( 0.23 ) $ ( 0.35 ) $ ( 0.72 ) $ ( 0.75 )

The potential shares through share options of 9,537,918

and 10,290,982 for the three months ended March 31, 2024 and 2023, respectively, have been excluded from the calculation of diluted

net loss per share due to their anti-dilutive effect.

For the three months ended March 31, 2024, shares issuable upon the potential conversion of all of the Notes (as defined in Note 5.

“Non-current interest-bearing

loans and borrowings”) were excluded from the calculation of diluted loss per share because they were anti-dilutive.

The potential shares through outstanding share options of 9,640,204 as of June 30, 2024 (June 30, 2023:

9,739,383 ), have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect.

For the three and six months ended June 30, 2024, shares issuable upon the potential conversion of all of the Notes (as defined in Note 5.

“Non-current interest-bearing loans and borrowings”) were excluded from the calculation of diluted loss per share because they were anti-dilutive.

Diluted earnings per share for the Notes is calculated under the if-converted method in accordance with ASC 260, Earnings Per Share.

Income tax expense is recognized at an amount determined by multiplying the net loss before income taxes for the interim reporting period by

the Company’s estimated annual effective tax rate, adjusted for the tax effect of certain items recognized in full in the interim period.

As such, the effective tax rate in the condensed consolidated financial statements may differ from the

Company’s estimate of the effective tax rate for the Company’s audited financial statements for the year ending December 31, 2024.

The Company’s consolidated estimated effective tax rate for the three months ended March 31, 2024 was 1.5 %.

During the three months ended March 31, 2024, the Company recorded a tax charge of $ 0.4 million, compared to a tax charge for the three months ended March 31, 2023 of $ 0.3 million.

Income tax expense is recognized at an amount determined by multiplying the net loss before income taxes for the interim reporting period by the Company’s estimated annual effective tax rate, adjusted for the tax effect of certain items recognized in full in the interim period.

As such, the effective tax rate in the condensed consolidated financial statements may differ from the Company’s estimate of the effective tax rate for the Company’s consolidated financial statements for the year ending December 31, 2024.

The Company’s consolidated estimated effective tax rate for the six months ended June 30, 2024 w as 5.4 %.

During the six months ended June 30, 2024, the Company recorded a tax charge of $ 1.8 million, comp ared to a tax charge for the six months ended June 30, 2023 of $ 0.5 million.

The Company continues to benefit from the U.K.

large company, Research & Development Expenditure Credit, or RDEC, regime which can generate a cash rebate of up to 15 % of qualifying research and development expenditures incurred after April 1, 2023.

Tax credits receivable under the RDEC regime are recorded

“above the line” as a reduction from research and development expenses.

For the three months ended March 31, 2024, the Company excluded the United Kingdom from the calculation of the Annual Estimated Tax Rate, or AETR, as the Company

anticipates an ordinary loss in this jurisdiction for which no tax benefit can be recognized.

A net deferred tax asset of $ 10.8

million has been recognized as of March 31, 2024 (December 31, 2023:

$ 11.0 million) primarily representing research and development

credits and share-based compensation for one of the Company’s U.S.

subsidiaries, Immunocore LLC, following an annual assessment, or periodically as required, of all available and applicable information, including its forecasts of costs and

future profitability and the resulting ability to reverse the recognized deferred tax assets over a short period of time.

During the three months ended March 31, 2024, the Company received U.K.

tax credits of $ 0 relating to research and development expenditure in the year ended December 31, 2023.

During the three months ended March 31, 2024, the Company made tax payments of $ 0.1 million in relation to estimated U.S.

corporate income taxes for 2023.

large company, Research & Development Expenditure Credit ("RDEC") regime which can generate a cash rebate of up t o 15 % of qualifying research and development expenditures incurred after April 1, 2023.

Tax credits receivable under the RDEC regime are recorded "above the line" as a reduction from research and development expenses.

For the three and six months ended June 30, 2024 , the Company excluded the United Kingdom from the calculation of the annual estimated tax rate as the Company anticipates an ordinary loss in this jurisdiction for which no tax benefit can be recognized.

A net deferred tax asset o f $ 10.1 m illion has been recognized as of June 30, 2024 ( December 31, 2023 :

$ 11.0 million) primarily representing research and development credits and share-based compensation for one of the Company’s U.S.

subsidiaries, Immunocore LLC, following an annual assessment, or periodically as required, of all available and applicable information, including its forecasts of costs and future profitability and the resulting ability to reverse the recognized deferred tax assets over a short period of time.

Commitments and contingencies

Lease commitments

The maturities of operating lease liabilities as of March 31, 2024 are as follows (in thousands):

The maturities of operating lease liabilities as of June 30, 2024 are as follows (in thousands):

2029 and thereafter

4 unchanged sentences

The Company enters into a number of manufacturing commitments for the future purchase of materials and contract manufacturing services.

majority of such contracts can be cancelled on reasonable notice, due to the significant ongoing expenditure associated with the Company’s programs, including brenetafusp (IMC-F106C), the Company estimates it has noncancellable commitments in

relation to the development and supply of product candidates totaling, $ 11.7 million, which are expected to be paid during the

remainder of 2024.

While the majority of such contracts can be cancelled on reasonable notice, due to the significant ongoing expenditure associated with the Company’s programs, including brenetafusp (IMC-F106C), the Company estimates it has noncancellable commitments in relation to the development and supply of product candidates totaling $ 15.5 million, which are expected to be paid during the remainder of 2024.

Legal proceedings

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements